SHIRLEY ANN NAGEL
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- MOUNT DORA, FL
- NPI
- 1043213366
- Received
- $369,365 in 206 records, 2019 to 2025 ($2,981 general, $366,383 research)
- As principal investigator
- $4,318,021 of research payments to others in 826 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 2 | $56 |
| 2024 | General payment | 1 | $24 |
| 2024 | Research payment | 1 | $12,042 |
| 2023 | General payment | 2 | $36 |
| 2023 | Research payment | 2 | $9,527 |
| 2022 | General payment | 4 | $62 |
| 2022 | Research payment | 2 | $343,136 |
| 2021 | General payment | 58 | $943 |
| 2021 | Research payment | 1 | $1,678 |
| 2020 | General payment | 61 | $975 |
| 2019 | General payment | 72 | $881 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 6 | $366,383 |
| Food and Beverage | 200 | $2,981 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-09-23 | Exact Sciences Corporation | $17 | Food and Beverage | In-kind items and services | The Cologuard Plus Collection Kit Device, Oncology | 2025 | |
| 2025-05-14 | REVANCE THERAPEUTICS, INC. | $39 | Food and Beverage | In-kind items and services | DAXXIFY Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2024-09-24 | Eli Lilly and Company | $12,042 | Research payment | Cash or cash equivalent | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 | |
| 2024-04-24 | Dexcom, Inc. | $24 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2024 | |
| 2023-04-12 | Eli Lilly and Company | $2,633 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-04-12 | Dexcom, Inc. | $17 | Food and Beverage | In-kind items and services | Dexcom G6 Transmitter Medical Supply, Endocrinology | 2023 | |
| 2023-02-16 | Bayer Healthcare Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-01-10 | Eli Lilly and Company | $6,894 | Research payment | In-kind items and services | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 | |
| 2022-11-01 | Eli Lilly and Company | $331,021 | Research payment | Cash or cash equivalent | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-04-04 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | LEQVIO Drug, CARDIOVASCULAR | 2022 | |
| 2022-03-31 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-03-08 | Eli Lilly and Company | $12,115 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-02-02 | Merck Sharp & Dohme LLC | $14 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2022 | |
| 2022-01-28 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2022 | |
| 2021-12-17 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-12-14 | Abbott Laboratories | $12 | Food and Beverage | In-kind items and services | FreeStyle Libre 2 Device, Diabetes Care | 2021 | |
| 2021-12-13 | Teva Pharmaceuticals USA, Inc. | $13 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2021 | |
| 2021-12-09 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-12-07 | Dexcom, Inc. | $22 | Food and Beverage | In-kind items and services | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | 2021 | |
| 2021-12-06 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-12-02 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-11-18 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-11-17 | Merck Sharp & Dohme LLC | $13 | Food and Beverage | In-kind items and services | BELSOMRA Drug, NEUROSCIENCE | 2021 | |
| 2021-11-15 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-11-03 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-10-11 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-10-08 | Eli Lilly and Company | $1,678 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2021 | |
| 2021-10-06 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-10-05 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2021 | |
| 2021-09-29 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-09-22 | VistaPharm, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Thyquidity Drug, Hypothyroidism | 2021 | |
| 2021-09-16 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-09-01 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2021 | |
| 2021-08-30 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2021-08-23 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-08-16 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-08-09 | Dexcom, Inc. | $16 | Food and Beverage | In-kind items and services | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | 2021 | |
| 2021-07-21 | Astellas Pharma US Inc | $12 | Food and Beverage | In-kind items and services | MYRBETRIQ Drug, UROLOGY | 2021 | |
| 2021-07-19 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-07-12 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | PREMARIN Drug, WOMENS HEALTH | 2021 | |
| 2021-07-08 | Dexcom, Inc. | $21 | Food and Beverage | In-kind items and services | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | 2021 | |
| 2021-06-30 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2021 | |
| 2021-06-28 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2021 | |
| 2021-06-21 | Biohaven Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2021 | |
| 2021-06-07 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-05-26 | NESTLE HEALTHCARE NUTRITION INC. | $15 | Food and Beverage | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2021 | |
| 2021-05-24 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2021 | |
| 2021-05-19 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-05-19 | Novo Nordisk Inc | $7 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-05-13 | Dexcom, Inc. | $17 | Food and Beverage | In-kind items and services | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | 2021 | |
| 2021-05-10 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-05-06 | Novo Nordisk Inc | $2 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-05-05 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2021 | |
| 2021-04-28 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2021-04-15 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-04-05 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-03-31 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-03-29 | NESTLE HEALTHCARE NUTRITION INC. | $16 | Food and Beverage | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2021 | |
| 2021-03-24 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-03-22 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2021 | |
| 2021-03-17 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2021 | |
| 2021-03-15 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-03-10 | AstraZeneca Pharmaceuticals LP | $38 | Food and Beverage (5 payments) | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-03-08 | Daiichi Sankyo Inc. | $21 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2021 | |
| 2021-03-01 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-02-24 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-02-17 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2021 | |
| 2021-02-10 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-01-27 | Teva Pharmaceuticals USA, Inc. | $13 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2021 | |
| 2021-01-25 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2021 | |
| 2021-01-21 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-01-12 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2021 | |
| 2021-01-06 | Astellas Pharma US Inc | $15 | Food and Beverage | In-kind items and services | MYRBETRIQ Drug, UROLOGY | 2021 | |
| 2020-12-08 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2020 | |
| 2020-12-07 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, GASTROENTEROLOGY | 2020 | |
| 2020-12-01 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2020 | |
| 2020-11-18 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-11-11 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-11-07 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-11-04 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | ANORO ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-10-27 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-10-14 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BREZTRI AEROSPHERE Drug, Respiratory | 2020 | |
| 2020-10-07 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2020 | |
| 2020-09-29 | Kowa Pharmaceuticals America, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2020 | |
| 2020-09-22 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-09-15 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2020 | |
| 2020-09-09 | Allergan, Inc. | $20 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2020 | |
| 2020-09-08 | Merck Sharp & Dohme LLC | $16 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2020 | |
| 2020-09-02 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-09-01 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | CHANTIX Drug, NEUROSCIENCE;TOBACCO DEPENDENCE | 2020 | |
| 2020-08-26 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2020 | |
| 2020-08-19 | Allergan, Inc. | $14 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2020 | |
| 2020-08-18 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | ANORO ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-08-05 | Arbor Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | Horizant Drug, Sleep | 2020 | |
| 2020-08-04 | Amgen Inc. | $11 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2020 | |
| 2020-07-29 | Amarin Pharma, Inc. | $18 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-07-28 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | CHANTIX Drug, NEUROSCIENCE;TOBACCO DEPENDENCE | 2020 | |
| 2020-07-22 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-07-21 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | ANORO ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-07-15 | Amneal Pharmaceuticals LLC | $19 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2020 | |
| 2020-07-14 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-06-24 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-06-23 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-06-22 | GlaxoSmithKline, LLC. | $26 | Food and Beverage | In-kind items and services | BREO ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-06-18 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-06-17 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-06-16 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-06-10 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2020 | |
| 2020-06-09 | Janssen Pharmaceuticals, Inc | $22 | Food and Beverage | In-kind items and services | INVOKANA Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-06-03 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-05-27 | Allergan, Inc. | $17 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2020 | |
| 2020-05-26 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-05-06 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2020 | |
| 2020-05-05 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2020 | |
| 2020-04-14 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-03-25 | Amgen Inc. | $12 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2020 | |
| 2020-03-11 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2020 | |
| 2020-03-03 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | BASAGLAR Drug, Diabetes | 2020 | |
| 2020-02-26 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | ANORO ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-02-25 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SYNTHROID Drug, IMMUNOLOGY | 2020 | |
| 2020-02-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15 | Food and Beverage | In-kind items and services | XIFAXAN Drug, GASTROENTEROLOGY | 2020 | |
| 2020-02-12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18 | Food and Beverage | In-kind items and services | XIFAXAN Drug, GASTROENTEROLOGY | 2020 | |
| 2020-02-12 | Amneal Pharmaceuticals LLC | $15 | Food and Beverage | In-kind items and services | UNITHROID Drug, ENDOCRINOLOGY | 2020 | |
| 2020-02-11 | SANOFI-AVENTIS U.S. LLC | $23 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrinology | 2020 | |
| 2020-02-11 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-02-05 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2020 | |
| 2020-02-04 | MILLICENT US INC | $20 | Food and Beverage | In-kind items and services | Femring Drug, Treat Symptoms of Menopause | 2020 | |
| 2020-01-22 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-01-21 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2020 | |
| 2020-01-15 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | ENTRESTO Drug, CARDIOVASCULAR | 2020 | |
| 2020-01-08 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2020 | |
| 2020-01-08 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, GASTROENTEROLOGY | 2020 | |
| 2020-01-07 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage (18 payments) | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-01-07 | SANOFI-AVENTIS U.S. LLC | $22 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Biological, Endocrinology | 2020 | |
| 2019-12-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-12-12 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | Creon Drug, Endocrinology | 2019 | |
| 2019-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-12-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-11-26 | Kowa Pharmaceuticals America, Inc. | $10 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2019 | |
| 2019-11-20 | Allergan, Inc. | $18 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2019 | |
| 2019-11-13 | Janssen Pharmaceuticals, Inc | $10 | Food and Beverage | In-kind items and services | INVOKANA Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-11-12 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2019 | |
| 2019-11-05 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | Synthroid Drug, Endocrinology | 2019 | |
| 2019-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-10-29 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2019 | |
| 2019-10-23 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | CHANTIX Drug, NEUROSCIENCE;TOBACCO DEPENDENCE | 2019 | |
| 2019-10-22 | Teva Pharmaceuticals USA, Inc. | $11 | Food and Beverage | In-kind items and services | AJOVY Drug, Central Nervous System | 2019 | |
| 2019-10-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-10-15 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2019 | |
| 2019-10-09 | TherapeuticsMD, Inc. | $16 | Food and Beverage | In-kind items and services | IMVEXXY Drug, OBSTETRICSGYNECOLOGY WOMEN'S HEALTH | 2019 | |
| 2019-10-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-10-02 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-10-01 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | SYMBICORT Drug, Respiratory | 2019 | |
| 2019-09-24 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | Synthroid Drug, Endocrinology | 2019 | |
| 2019-09-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-09-17 | Janssen Pharmaceuticals, Inc | $14 | Food and Beverage | In-kind items and services | INVOKANA Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-09-10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, GASTROENTEROLOGY | 2019 | |
| 2019-09-10 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | ANORO Drug, RESPIRATORY | 2019 | |
| 2019-09-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-09-04 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | CHANTIX Drug, NEUROSCIENCE;TOBACCO DEPENDENCE | 2019 | |
| 2019-09-03 | TherapeuticsMD, Inc. | $16 | Food and Beverage | In-kind items and services | IMVEXXY Drug, OBSTETRICSGYNECOLOGY WOMEN'S HEALTH | 2019 | |
| 2019-08-27 | Allergan, Inc. | $24 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2019 | |
| 2019-08-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-08-13 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | ANORO Drug, RESPIRATORY | 2019 | |
| 2019-08-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-07-30 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | Synthroid Drug, Endocrinology | 2019 | |
| 2019-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-07-18 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | Creon Drug, Endocrinology | 2019 | |
| 2019-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-06-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-06-04 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | ANORO Drug, RESPIRATORY | 2019 | |
| 2019-06-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-05-29 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | Synthroid Drug, Endocrinology | 2019 | |
| 2019-05-28 | SANOFI-AVENTIS U.S. LLC | $13 | Food and Beverage | In-kind items and services | TOUJEO Drug, DIABETES | 2019 | |
| 2019-05-22 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | LYRICA Drug, NEUROSCIENCE;PAIN | 2019 | |
| 2019-05-21 | AstraZeneca Pharmaceuticals LP | $11 | Food and Beverage | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-05-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-05-14 | Allergan, Inc. | $13 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2019 | |
| 2019-05-11 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2019 | |
| 2019-05-08 | Mylan Specialty L.P. | $15 | Food and Beverage | In-kind items and services | Yupelri Drug, Respiratory and Allergy | 2019 | |
| 2019-05-01 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2019 | |
| 2019-04-30 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-04-24 | TherapeuticsMD, Inc. | $19 | Food and Beverage | In-kind items and services | IMVEXXY Drug, OBSTETRICSGYNECOLOGY WOMEN'S HEALTH | 2019 | |
| 2019-04-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-04-17 | Merck Sharp & Dohme LLC | $12 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2019 | |
| 2019-04-16 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | ANORO Drug, RESPIRATORY | 2019 | |
| 2019-04-10 | Allergan, Inc. | $20 | Food and Beverage | In-kind items and services | BYSTOLIC Drug, CARDIOVASCULAR | 2019 | |
| 2019-04-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-03-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2019 | |
| 2019-03-20 | Merck Sharp & Dohme LLC | $12 | Food and Beverage | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | 2019 | |
| 2019-03-19 | SANOFI-AVENTIS U.S. LLC | $14 | Food and Beverage | In-kind items and services | TOUJEO Drug, DIABETES | 2019 | |
| 2019-03-13 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-03-12 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2019 | |
| 2019-03-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-03-06 | IRONWOOD PHARMACEUTICALS, INC | $17 | Food and Beverage | In-kind items and services | Linzess Drug, Gastroenterology | 2019 | |
| 2019-02-27 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | Synthroid Drug, Endocrinology | 2019 | |
| 2019-02-20 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | Aimovig Biological, Neuroscience | 2019 | |
| 2019-02-19 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2019 | |
| 2019-02-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8 | Food and Beverage | In-kind items and services | SPIRIVA RESPIMAT Drug, RESPIRATORY | 2019 | |
| 2019-02-06 | SANOFI-AVENTIS U.S. LLC | $12 | Food and Beverage | In-kind items and services | SOLIQUA 100/33 Drug, DIABETES | 2019 |
The latest 200 records of 206.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $1,769 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-12-31 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY | $5,612 | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and sa | 2025 |
| 2025-12-17 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $992 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-12-12 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $752 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-12-09 | Eli Lilly and Company | ADULT MEDICINE OF LAKE COUNTY | $9,725 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-11-29 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $2,167 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-11-05 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $20,676 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-10-31 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $1,716 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-10-15 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $1,368 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-10-09 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $16,915 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-10-08 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $3,504 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-09-25 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $1,151 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-09-24 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $9,283 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-09-09 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $12,590 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-09-04 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $25,270 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-08-06 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $19,389 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-08-05 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $4,317 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-07-14 | Eli Lilly and Company | ADULT MEDICINE OF LAKE COUNTY | $1,500 | EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST | 2025 |
| 2025-07-02 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $19,167 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-03 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $46,553 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-05-22 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $3,350 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-05-07 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $12,550 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-04-28 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $1,440 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-04-03 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $11,488 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-03-25 | Eli Lilly and Company | ELLIGO HEALTH RESEARCH INC | $625,907 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-03-14 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY INC | $3,815 | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2025 |
| 2025-03-07 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $49,523 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2025-03-01 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $13,034 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2025 |
| 2025-02-10 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $9,024 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2025 |
| 2025-02-06 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $4,513 | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of | 2025 |
| 2025-02-04 | Eli Lilly and Company | ADULT MEDICINE OF LAKE COUNTY | $1,370,205 | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2025 |
| 2025-01-31 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $234 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-27 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $15,495 | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2025 |
| 2025-01-06 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $54,351 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2024-12-31 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $4,992 | M21-341 ATH Ph 2b Armour Thyroid vs Synthetic T4 (ATH-MD-01) (3014-301-002) | 2024 |
| 2024-12-30 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $8,759 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-12-09 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $1,297 | EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST | 2024 |
| 2024-12-05 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $31,089 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-11-21 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY INC | $3,863 | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 |
| 2024-11-20 | PFIZER INC. | CLIN RES ADULT MED OF LAKE COUNTY | $388 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2024 |
| 2024-11-15 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY INC | $853 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COM | 2024 |
| 2024-11-07 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $16,311 | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-10-29 | Eli Lilly and Company | ADULT MEDICINE OF LAKE COUNTY | $37,557 | EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST | 2024 |
| 2024-10-28 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $6,315 | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2024 |
| 2024-10-03 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $20,732 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-09-04 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $10,822 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-08-20 | Eli Lilly and Company | ELLIGO HEALTH RESEARCH INC | $19,017 | EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST | 2024 |
| 2024-07-25 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $11,500 | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 |
| 2024-06-05 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY INC | $396 | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 |
| 2024-05-09 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY INC | $10,336 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2024 |
| 2024-04-30 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $1,000 | NN9535-4820 | 2024 |
| 2024-04-30 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $5,850 | NN9535-4820 | 2024 |
| 2024-04-26 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY INC | $9,330 | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 |
| 2024-03-28 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY INC | $11,876 | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL | 2024 |
| 2024-01-24 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $1,600 | NN9535-4820 | 2024 |
| 2024-01-09 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $2,589 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2024-01-04 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $2,013 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-02 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $161,077 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-02 | Eli Lilly and Company | PROGRESSIVE MEDICAL CONCEPTS LLC | $11,607 | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PL | 2024 |
| 2024-01-02 | Eli Lilly and Company | ELLIGO HEALTH RESEARCH INC | $234,080 | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
| 2023-12-31 | ABBVIE INC. | ADULT MEDICINE OF LAKE COUNTY | $388 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and An | 2023 |
| 2023-12-13 | Chiesi USA, Inc. | ELLIGO HEALTH RESEARCH INC | $5,500 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2023 |
| 2023-11-16 | Chiesi USA, Inc. | ELLIGO HEALTH RESEARCH INC | $5,000 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2023 |
| 2023-10-09 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $2,024 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2023-08-22 | Chiesi USA, Inc. | ELLIGO HEALTH RESEARCH INC | $2,000 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2023 |
| 2023-08-21 | Eli Lilly and Company | PROGRESSIVE MEDICAL CONCEPTS LLC | $61,594 | A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLAC | 2023 |
| 2023-07-03 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $77,195 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-06-12 | Chiesi USA, Inc. | ELLIGO HEALTH RESEARCH INC | $500 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2023 |
| 2023-05-15 | Chiesi USA, Inc. | ELLIGO HEALTH RESEARCH INC | $587 | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2023 |
| 2023-04-24 | Chiesi USA, Inc. | ELLIGO HEALTH RESEARCH INC | $5,000 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two | 2023 |
| 2023-04-21 | Eli Lilly and Company | COMPASS RESEARCH EAST LLC | $442 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-02-22 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $7 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AN | 2023 |
| 2023-02-22 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $200 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AN | 2023 |
| 2023-02-14 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $70 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AN | 2023 |
| 2023-02-14 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $700 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AN | 2023 |
| 2023-02-13 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $700 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AN | 2023 |
| 2023-02-13 | AstraZeneca Pharmaceuticals LP | Elligo Health Research, Inc | $7,174 | A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy | 2023 |
| 2023-02-13 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $70 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AN | 2023 |
| 2023-01-11 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $110 | NN9535-4820 | 2023 |
| 2023-01-03 | Eli Lilly and Company | ELLIGO HEALTH RESEARCH INC | $729,966 | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | 2023 |
| 2022-12-08 | Chiesi USA, Inc. | ELLIGO HEALTH RESEARCH INC | $350 | A 52-WEEK, PLACEBO- AND ACTIVE- CONTROLLED (ROFLUMILAST, DALIRESP 500) STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO | 2022 |
| 2022-11-23 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $7,250 | NN9535-4820 | 2022 |
| 2022-11-23 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $7,250 | NN9535-4820 | 2022 |
| 2022-11-21 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $1,309 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AN | 2022 |
| 2022-11-15 | PFIZER INC. | ADULT MEDICINE OF LAKE COUNTY | $2,104 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED DOSE RANGING DOSE FINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AN | 2022 |
| 2022-10-21 | Novo Nordisk AS | Elligo Health Research, Inc | $663 | NN1436-4481 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $5 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $4 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $5 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $4 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $4 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $4 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $5 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $4 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $30 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $4 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $3 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $5 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $5 | NN9535-4820 | 2022 |
| 2022-10-07 | Novo Nordisk AS | ADULT MEDICINE OF LAKE COUNTY, INC | $5 | NN9535-4820 | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Mount Dora, FL, county Lake County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Mount Dora, FL | County Lake County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 17,278 | 412,924 | 22,416,077 |
| Population, 2020 census P1 | 16,341 | 383,956 | 21,538,187 |
| Median age B01002 | 48.8 | 46.5 | 42.6 |
| Under 18 B01001 | 16.6% | 19.0% | 19.5% |
| 65 and over B01001 | 33.5% | 26.6% | 21.3% |
| Households B11001 | 7,646 | 164,497 | 8,752,810 |
| Foreign born B05002 | 11.3% | 10.7% | 21.9% |
| Median household income B19013 | $74,537 | $73,161 | $74,568 |
| Median family income B19113 | $86,271 | $89,061 | $89,891 |
| Per capita income B19301 | $45,706 | $38,577 | $42,609 |
| Poverty rate B17001 | 11.8% | 8.9% | 12.6% |
| Unemployment rate B23025 | 5.9% | 5.0% | 4.8% |
| Civilian labor force B23025 | 7,152 | 184,692 | 11,016,578 |
| Mean commute (minutes) B08013 | 29.7 | 30.2 | 28.0 |
| Bachelor's degree or higher B15003 | 38.6% | 27.8% | 34.1% |
| Housing units B25001 | 8,621 | 187,580 | 10,256,470 |
| Owner-occupied B25003 | 61.7% | 77.6% | 67.6% |
| Renters B25003 | 38.3% | 22.4% | 32.4% |
| Median home value B25077 | $381,900 | $318,400 | $359,000 |
| Median gross rent B25064 | $1,722 | $1,586 | $1,669 |
| White, not Hispanic B03002 | 60.4% | 63.6% | 50.4% |
| Black B03002 | 13.0% | 10.2% | 14.6% |
| Hispanic or Latino B03002 | 23.7% | 18.8% | 27.4% |
| Asian B03002 | 0.3% | 2.0% | 2.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Mount Dora, FL.
Comments